virus covid-19 vaccine

OSE’s Covid-19 vaccine shows promise in preclinical studies

Reading now: 102
www.pharmaceutical-technology.com

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.OSE Immunotherapeutics has reported positive data from preclinical and human ex-vivo studies of its Covid-19 vaccine candidate, CoVepiT.

The company published the findings online on BioRxiv. Based on optimised peptides improved with artificial intelligence algorithms, CoVepiT elicits a lasting sentinel T lymphocyte immune response against Covid-19.

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA